0.98
-0.03(-2.97%)
Currency In USD
| Previous Close | 1.01 |
| Open | 0.99 |
| Day High | 1.07 |
| Day Low | 0.97 |
| 52-Week High | 2.57 |
| 52-Week Low | 0.88 |
| Volume | 479,060 |
| Average Volume | 867,482 |
| Market Cap | 59.85M |
| PE | -1.02 |
| EPS | -0.96 |
| Moving Average 50 Days | 1.11 |
| Moving Average 200 Days | 1.32 |
| Change | -0.03 |
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
GlobeNewswire Inc.
Feb 26, 2026 12:00 PM GMT
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process Received FDA clearance of INDs for TSC-102-A01 and TSC-102-A03 targeting CD45, for patients with HLA types A*01:01 and A
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 12:00 PM GMT
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 06, 2025 10:30 PM GMT
Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up remained relapse-free vs. 1/4 (25%) in the control a